financetom
Business
financetom
/
Business
/
Zomato agrees to buy Uber Eats in all-stock deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Zomato agrees to buy Uber Eats in all-stock deal
Jan 20, 2020 10:40 PM

Online food delivery startup Zomato has agreed to acquire Uber's food delivery business in India—Uber Eats—in an all-stock deal, which gives Uber Technologies a 10 percent stake in Zomato.

The deal, valued at $300 million, will give Zomato over 50 percent marketshare in food delivery segment.

“Zomato Media Private Ltd. has signed a definitive agreement to acquire Uber's food delivery business in India in an all-stock transaction, which gives Uber 9.99% ownership in Zomato,” said Info Edge, which has about 23 percent stake in Zomato, in a regulatory filing.

Uber Eats in India will discontinue operations and direct restaurants, delivery partners, users of the Uber Eats apps to the Zomato platform, effective today, according to the filing, dated January 21.

"India remains an exceptionally important market to Uber and we will continue to invest in growing our local Rides business," said Dara Khosrowshahi, Uber's chief executive officer.

Uber Eats in India accounted for 3 percent of the business' gross bookings globally, but more than a quarter of its adjusted EBITDA loss in the first three quarters of 2019, Uber said.

"You can still get rides via the Uber app, which remains active and available. And you can still use Uber Eats if you're travelling outside India," said Uber in a statement.

Uber Eats India, which was serving 41 cities and has partnership with 26,000 restaurants, has 12 percent marketshare in the food delivery category.

Zomato is valued at around $3 billion after the startup raised $150 million from Alibaba affiliate Ant earlier this month.

Zomato confirmed that the $150 million fundraise was part of a larger round, but did not give further details.

The Gurugram-based restaurant aggregator recorded a loss of about Rs 1,000 crore in the financial year ended in March 2019 on revenues of Rs 1,400 crore.

First Published:Jan 21, 2020 7:40 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Jun 5, 2024
SHANGHAI (Reuters) -Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have...
KKR, GIP lead $25 billion regional infrastructure tie-up, US says
KKR, GIP lead $25 billion regional infrastructure tie-up, US says
Jun 5, 2024
SINGAPORE, June 6 (Reuters) - KKR, Global Infrastructure Partners (GIP) and the Indo-Pacific Partnership for Prosperity have formed a coalition to invest $25 billion in infrastructure in the Indo-Pacific region, U.S. Commerce Secretary Gina Raimondo said on Thursday. Raimondo, speaking in Singapore, said investment would include green data centres in Indonesia, renewable energy in the Philippines and smart metres and...
Meta gets 11 EU complaints over use of personal data to train AI models
Meta gets 11 EU complaints over use of personal data to train AI models
Jun 5, 2024
BRUSSELS (Reuters) - Meta Platforms ( META ) was hit with 11 complaints on Thursday over proposed changes that would see it use personal data to train its artificial intelligence models without asking for consent, which may breach European Union privacy rules. Advocacy group NOYB (none of your business) urged national privacy watchdogs to act immediately to halt such use,...
FOCUS-Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
FOCUS-Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Jun 5, 2024
SHANGHAI, June 6 (Reuters) - Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved